Holen Sie sich die Stockscreener-App
9.86
1.24%
0.15
Schlusskurs vom Vortag:
$9.71
Offen:
$9.8
24-Stunden-Volumen:
355.52K
Relative Volume:
0.06
Marktkapitalisierung:
$2.16B
Einnahmen:
$52.04M
Nettoeinkommen (Verlust:
$-290.50M
KGV:
-9.2993
EPS:
-1.0603
Netto-Cashflow:
$-216.89M
1W Leistung:
+6.73%
1M Leistung:
+21.81%
6M Leistung:
-7.53%
1J Leistung:
+37.00%
1-Tages-Spanne:
$9.655
$9.91
1-Wochen-Bereich:
$9.08
$9.91
52-Wochen-Spanne:
$6.2301
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Firmenname
Ocular Therapeutix Inc
Sektor
Branche
Telefon
781-357-4000
Adresse
14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA
Compare OCUL vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
9.845 | 2.13B | 52.04M | -290.50M | -216.89M | -1.0603 |
VRTX
Vertex Pharmaceuticals Inc
|
425.97 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
712.28 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.79 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
300.85 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
306.00 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-15 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-04-08 | Eingeleitet | William Blair | Outperform |
| 2025-03-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-03-11 | Eingeleitet | Needham | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-20 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-02-09 | Eingeleitet | BofA Securities | Buy |
| 2023-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-08-10 | Fortgesetzt | Berenberg | Buy |
| 2021-08-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-11-13 | Bestätigt | Raymond James | Strong Buy |
| 2020-08-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-03 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-05-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-21 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-11-15 | Eingeleitet | Raymond James | Strong Buy |
| 2018-09-07 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2017-07-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-07-12 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-06-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-08-11 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten
Equity-Based Pay at Ocular Therapeutix Raises Insider Trading Perception and Governance Risks - TipRanks
Ocular Therapeutix reports Q1 EPS (40c), consensus (31c) - TipRanks
Ocular Therapeutix Q1 Earnings Call Highlights - Yahoo Finance
Ocular Therapeutix Q1 2026 Earnings Call Transcript - MarketBeat
OCUL: AXPAXLI's phase III success in wet AMD drives NDA plans and commercial readiness, backed by strong cash reserves - TradingView
Ocular Therapeutix's Q1 Net Loss Widens, Revenue Rises - marketscreener.com
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings call transcript: Ocular Therapeutix Q1 2026 shows earnings miss By Investing.com - Investing.com India
Earnings call transcript: Ocular Therapeutix Q1 2026 shows earnings miss - Investing.com
Ocular Therapeutix Inc (NASDAQ:OCUL) Misses on Revenue and EPS in Q1 2026, Stock Dips - ChartMill
OCULAR THERAPEUTIX ($OCUL) Releases Q1 2026 Earnings - Quiver Quantitative
Earnings Flash (OCUL) Ocular Therapeutix Posts Q1 Loss $0.40 a Share, vs. FactSet Est of $0.31 Loss - marketscreener.com
Ocular Therapeutix (NASDAQ:OCUL) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings - TradingView
Ocular Therapeutix: Q1 Earnings Snapshot - marketscreener.com
Ocular Therapeutix 1Q 2026: Revenue $10.79M, Net income ($88.61M), EPS ($0.4) — 10-Q Summary - TradingView
[10-Q] OCULAR THERAPEUTIX, INC Quarterly Earnings Report - Stock Titan
Ocular Therapeutix reports Q1 2026: $10.8M revenue, $88.6M net loss, $666.7M cash - TradingView
OCUL: AXPAXLI's Phase 3 success in wet AMD drives NDA plans amid rising R&D costs and strong cash position - TradingView
Ocular Therapeutix (NASDAQ: OCUL) widens Q1 loss while advancing AXPAXLI Phase 3 trials - Stock Titan
Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights - The Manila Times
MSN Money - MSN
Ocular Therapeutix Q1 2026 earnings preview - MSN
Ocular Therapeutix (OCUL) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance UK
Ocular Therapeutix earnings up next as AXPAXLI NDA looms By Investing.com - Investing.com South Africa
Ocular Therapeutix earnings up next as AXPAXLI NDA looms - Investing.com
Assessing Ocular Therapeutix (OCUL) Valuation After New AXPAXLI Trial Progress And FDA Preparation - Sahm
OCULAR THERAPEUTIX, INC ($OCUL) CEO 2025 Pay Revealed - Quiver Quantitative
How Investors Are Reacting To Ocular Therapeutix (OCUL) Advancing AXPAXLI Toward NDA After Positive SOL-1 Trial - Yahoo Finance
Ocular Therapeutix (NASDAQ: OCUL) outlines 2026 proxy and 10M-share incentive plan increase - Stock Titan
[ARS] OCULAR THERAPEUTIX, INC SEC Filing - Stock Titan
Ocular Therapeutix Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI in Wet AMD - marketscreener.com
OCUL Stock Price, Quote & Chart | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill
How The SOL-1 Readout Is Reframing The Story For Ocular Therapeutix (OCUL) - Yahoo Finance
OCUL stock surges overnight ahead of crucial wet AMD data readout, Sanofi takeover buzz builds - MSN
Ocular Therapeutix (OCUL) Begins Patient Enrollment in Axpali Tr - GuruFocus
Ocular Therapeutix Inc. (OCUL) Appears Highly Attractive Following SOL-1 Clinical Trial Data - Insider Monkey
Ocular Therapeutix enrolls first patient in wet AMD extension trial By Investing.com - Investing.com Australia
Ocular Therapeutix enrolls first patient in wet AMD extension trial - Investing.com
First wet AMD patient enters 3-year AXPAXLI follow-up study - Stock Titan
Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD - Sahm
Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences - Sahm
Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026 - The Manila Times
May 5 at 8 a.m. ET: Ocular Therapeutix to discuss Q1 results - Stock Titan
Ocular Therapeutix gains amid takeover speculation - MSN
Ocular Therapeutix Says FDA Talks Progressing as It Eyes AXPAXLI NDA for Wet AMD on SOL-1 Data - MarketBeat
Ocular Therapeutix, Inc. $OCUL Stock Position Lessened by Deltec Asset Management LLC - MarketBeat
Ocular lines up May talks on AMD trial data and investor webcasts - Stock Titan
Ocular Therapeutix prices $475M stock offering - MSN
Finanzdaten der Ocular Therapeutix Inc-Aktie (OCUL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.78%
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):